Vaishali Pharma Ltd vs Valiant Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Vaishali Pharma Ltd is ₹ 7.61 as of 30 Apr 15:30 . The P/E Ratio of Vaishali Pharma Ltd is 0 as of March 2023 .The P/E Ratio of Valiant Laboratories Ltd is 0 as of March 2023 . The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Valiant Laboratories Ltd is ₹ 0 crore as of March 2023 . The revenue of Vaishali Pharma Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 25.54 crore. This represent the decline of -100% The revenue of Valiant Laboratories Ltd for the Mar '25 is ₹ 55.47 crore as compare to the Dec '25 revenue of ₹ 53.09 crore. This represent the growth of 4.48% The ebitda of Vaishali Pharma Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 2.45 crore. This represent the decline of -100% The ebitda of Valiant Laboratories Ltd for the Mar '25 is ₹ 1.51 crore as compare to the Dec '25 ebitda of ₹ -0.26 crore. This represent the decline of -680% The net profit of Vaishali Pharma Ltd changed from ₹ 1.28 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of -100.00% The net profit of Valiant Laboratories Ltd changed from ₹ -0.51 crore to ₹ 0.7 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Valiant Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

About Valiant Laboratories Ltd

Valiant Laboratories Limited was originally formed as a Partnership Firm as M/s.
Bharat Chemicals' through deed of partnership dated October 17, 1980.
The said Partnership Firm, M/s.
Bharat Chemicals thereafter converted into a Public Company to 'Valiant Laboratories Limited' via Certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies. The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol.
The Company gradually, commenced manufacturing of Paracetamol by late 1982.

FAQs for the comparison of Vaishali Pharma Ltd and Valiant Laboratories Ltd

Which company has a larger market capitalization, Vaishali Pharma Ltd or Valiant Laboratories Ltd?

Market cap of Vaishali Pharma Ltd is 99 Cr while Market cap of Valiant Laboratories Ltd is 428 Cr

What are the key factors driving the stock performance of Vaishali Pharma Ltd and Valiant Laboratories Ltd?

The stock performance of Vaishali Pharma Ltd and Valiant Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Vaishali Pharma Ltd and Valiant Laboratories Ltd?

As of May 3, 2026, the Vaishali Pharma Ltd stock price is INR ₹7.61. On the other hand, Valiant Laboratories Ltd stock price is INR ₹78.85.

How do dividend payouts of Vaishali Pharma Ltd and Valiant Laboratories Ltd compare?

To compare the dividend payouts of Vaishali Pharma Ltd and Valiant Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.